Contemporary medicine has achieved significant success through standardized, symptom-oriented treatment protocols, especially in acute and infectious conditions, but it often overlooks individual variability and deeper etiological factors, leading to recurrence or incomplete cure. Ayurveda explains disease causation through Asatmyendriyartha Samyoga, Prajnaparadha, and Parinama, and emphasizes Hetuviparita Chikitsa-treating disease by counteracting its root cause. Unlike the disease-focused modern approach, Ayurveda prioritizes correction of faulty lifestyle, diet, and behavior, particularly Prajnaparadha, to restore systemic balance. Classical Ayurvedic texts and contemporary medical literature were systematically reviewed to examine the principles of Hetuviparita Chikitsa and to enable a comparative analysis with modern treatment approaches. Ayurveda explains disease through the Karya–Karana Siddhanta, emphasizing that Dosha imbalance triggered by causative factors (Nidana) leads to pathology, and hence prioritizes Hetuviparita Chikitsa-counteracting the root cause to restore Dhatusamya. Classical texts highlight that removal of Hetu, particularly Prajnaparadha, is central to both treatment and prevention. In contrast, contemporary medicine largely focuses on pathogen eradication and symptomatic relief, which may result in recurrence after discontinuation of therapy. Thus, Ayurveda adopts a holistic, immunity-enhancing and causation-based approach, whereas modern medicine emphasizes acute intervention and disease control. Hetuviparita Chikitsa is a core Ayurvedic principle focused on restoring balance by correcting the root cause of disease. Although modern medicine is highly effective in acute and infectious conditions, its symptom-centered approach may overlook systemic harmony. An integrative approach combining Ayurvedic causative correction with modern medical advances can promote more comprehensive and sustainable healthcare.
Diabetic dyslipidemia is a common metabolic complication of type 2 diabetes mellitus (T2DM), characterized by abnormal lipid metabolism that significantly elevates cardiovascular risk. In Ayurveda, this condition correlates with Medoroga occurring as a sequela of Prameha, where Agnimandya (impaired metabolic fire), Ama (toxic metabolic bioproducts), and Kapha‑Meda Dushti drive pathogenesis. Ayurvedic interventions aim to correct these root metabolic disturbances. Case Presentation: A 63‑year‑old male with a 10‑year history of T2DM presented with unexplained weight gain and impaired digestion. Despite ongoing oral hypoglycemic medication, his glycemic control remained suboptimal (HbA1c: 8.2%, FBS: 144mg/dL, PPBS: 230mg/dL). He was concurrently diagnosed with diabetic dyslipidemia, showing an elevated serum LDL cholesterol level of 171.3mg/dL. The patient was treated with Phalatrikadi Kwatha, Navaka Guggulu, and Triphala Churna as an adjunct to his ongoing oral hypoglycemic therapy, alongside customized Ayurvedic dietary and lifestyle modifications (Pathya Ahara‑Vihara). Results: Following 3 months of conservative management, the patient demonstrated significant improvement in clinical symptoms, glycemic indices (HbA1c decreased to 6.8%), and lipid profile metrics (serum LDL reduced to 152.6mg/dL), with zero adverse drug reactions. Conclusion: This case suggests that classical Ayurvedic formulations, when safely integrated as an adjunct to conventional oral hypoglycemic therapy, can significantly improve lipid pathways and metabolic homeostasis in diabetic dyslipidemia.
Pathya-Apathya (wholesome-unwholesome) diet and lifestyle are the fundamental principles in Ayurveda, prescribed according to disease conditions to enhance treatment outcomes. In the context of Rasachikitsa, classical texts emphasize specific Pathya and Apathya guidelines according to Rasoushadhis. This is because Rasoushadhis are Vijatiya Dravya, i.e. Nirendriya Dravya includes heavy metals, minerals. They differ from Sajatiya dravya, which are easily metabolized in the body. Rasoushadhis, despite undergoing Shodhana and Samskara, retain potent properties and may interact differently with dietary substances after administration. In present era, medicines are frequently taken without medical consultation. Neglect of Pathya–Apathya principles in Rasachikitsa increases risk of altered drug-food interactions and hazardous outcomes. This paper highlights probable Rasoushadhi- drug interactions and their impact on the body. Analysis indicates that Samyoga of Rasoushadhi with specific dietary substances may lead to either, reduced or exaggerated drug action or adverse drug reactions. For instance, when Kampilaka interacts with Nagveli Patra, the Rechana Karma of Kankushtha is significantly enhanced, resulting in Atiyoga. Conversely, substances belonging to the Kakarashtaka Varga inhibit the absorption of Parada within the body, thereby limiting its therapeutic utility. Similarly, Kulatha interacts with Shilajatu by breaking it down in the body, which diminishes the potency and effectiveness of Shilajatu. Hence knowledge of Pathya- Apathya is crucial in Rasachikitsa as it regulates Rasoushadhi–diet interactions, ensuring safe metabolism, preventing adverse effects, and enhancing therapeutic efficacy.
Background: Hypertensive urgency is characterized by severely elevated blood pressure without evidence of acute targetorgan damage and is associated with an increased risk of cardiovascular complications. Obesity, dyslipidaemia, and psychological stress are important contributors to persistent hypertension. Case Presentation: A 31-year-old obese male (BMI 30.09 kg/m²) presented with persistently elevated blood pressure of 210/150 mmHg despite recent initiation of telmisartan therapy. The patient had a 10-year history of hypertension and associated cardiovascular risk factors, including obesity, dyslipidaemia, sedentary lifestyle and chronic psychological stress. Laboratory investigations revealed elevated total cholesterol (248 mg/dL), triglycerides (448 mg/dL), LDL cholesterol (110.6 mg/dL), and VLDL cholesterol (89.6 mg/dL). Based on clinical evaluation and the absence of clinically evident acute target-organ involvement during evaluation, the condition was considered hypertensive urgency. Intervention: The patient was managed with an Ayurvedic treatment protocol comprising Sarpagandha Ghanavati, Pippalimoola Churna, Brahmi, Shankhapushpi, Panchatikta Kwatha, and Triphala Guggulu, along with dietary regulation, salt restriction, physical activity, stress management practices, and lifestyle modifications. The concomitant antihypertensive medication was gradually tapered according to clinical response under close medical supervision. Outcome: Over a follow-up period of approximately 70 days, blood pressure progressively reduced from 210/150 mmHg to 126/80 mmHg. Significant improvements were also observed in body mass index (30.09 to 27.7 kg/m²), perceived stress score (31 to 20), total cholesterol (248 to 127 mg/dL), triglycerides (448 to 145 mg/dL), LDL (110.6 to 65.4 mg/dL), and VLDL (89.6 to 29 mg/dL). No adverse events or treatment-related complications were reported. Conclusion: This case suggests that a comprehensive Ayurvedic intervention targeting obesity, dyslipidaemia, stress, and underlying pathogenic mechanisms may contribute to effective management of hypertensive urgency. The observed improvements in blood pressure and cardiovascular risk factors indicate the potential role of Ayurveda as an integrative approach in severe hypertension.
The safety of herbo-mineral-metallic preparations is frequently questioned in the contemporary context of global standardization, particularly due to their heavy metal compositions. The United States (2002–2003) reported cases of adult lead poisoning linked to Ayurvedic medicines, even though these medications have been successfully utilized for therapeutic purposes without observable side effects for millennia. This study aimed to evaluate the genotoxic potential of Garbhapala Rasa prepared with Shataputa Naga Bhasma — a lead-based herbo-mineral formulation — using the in vivo micronucleus (MN) assay and chromosomal aberration assay in Wistar albino rats of both sexes. Results demonstrated no discernible increase in MN frequency or DNA damage in Garbhapala Rasa-treated animals compared to vehicle control groups, confirming that the formulation was not genotoxic under the experimental conditions and test system employed.
